EVOLUS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
EVOLUS, INC. (EOLS) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $8.70 per share as of 2019-06-30, per its 10-Q filed 2019-08-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2019-08-12
- 2019-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $8.70.
- 2019-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $8.06.
- 2018-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $7.32; Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed $11.99.
- 2017-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $0.00.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2019-06-30 | $8.70 10-Q · filed 2019-08-12 | |
| 2019-03-31 | $8.06 10-Q · filed 2019-05-01 | |
| 2018-12-31 | $7.32 10-Q · filed 2019-08-12 | $11.99 10-K · filed 2019-03-20 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |